Citius Pharmaceuticals, Inc. 8-K

What Happened

• On May 15, 2026, Citius Pharmaceuticals, Inc. (CTXR) announced its results of operations for the second quarter of fiscal 2026 via a press release. The company furnished that press release as Exhibit 99.1 to its Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 15, 2026; Item reported: 2.02 (Results of Operations and Financial Condition).
• Press release announcing Q2 FY2026 results is furnished as Exhibit 99.1 and incorporated by reference.
• The filing includes an iXBRL interactive data cover file (Exhibit 104).
• The 8-K does not disclose additional items such as executive changes or transaction notices (no Item 5.02/1.01 entries in this filing).

Why It Matters

• This 8-K provides the company’s latest quarterly operating results and financial condition information that investors use to update earnings models, assess cash runway, and re-evaluate valuation and risk.
• Investors should read the Exhibit 99.1 press release for the specific revenue, profit/loss, cash balance, and any management commentary or guidance; the Form 8-K itself furnishes the release but does not expand beyond incorporating it by reference.